|
Pressure Bio, Target Discovery expand collaboration
June 2012
SHARING OPTIONS:
SOUTH EASTON, Mass.—Target Discovery Inc. (TDI) and Pressure
BioSciences Inc. (PBI) recently signed expanded strategic technology license
and supply agreements, granting TDI the right to use PBI’s patented Pressure
Cycling Technology platform for its entry into the clinical diagnostics testing
market. Initially, the services will target what TDI and PBI believe to be
unmet needs in treatment selection guidance for ovarian cancer. The agreement
includes a minimum royalty, to be replaced by an annual royalty once TDI meets
a specified level of sales, as well as a right of first negotiation and right
of first refusal. No specific financial details were disclosed. The agreements
follow a 2010 collaboration to combine PBI’s platform with TDI’s proprietary
reagents to enable the extraction of membrane protein biomarkers from human
tissue. Back |
|
||
|
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|